Related Experiment Videos

A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay

Lorenza Landi¹, Federico Cappuzzo¹

¹Onco-Hematology Department, AUSL Romagna, Ravenna, Italy.

Journal of Thoracic Disease

|September 22, 2017

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Clinical lung cancer·2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

The Lancet. Oncology·2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

High Prevalence of Superficial Metastases Supports Percutaneous Ultrasound-Guided Biopsy for Diagnosis and Molecular Profiling of Advanced Lung Cancer: Results from a Prospective Cohort.

Cancers·2026

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

See all related articles